| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | UBE2C |
| Uniprot No | O00762 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-179aa |
| 氨基酸序列 | ASQNRDPAA TSVAAARKGA EPSGGAARGP VGKRLQQELM TLMMSGDKGI SAFPESDNLF KWVGTIHGAA GTVYEDLRYK LSLEFPSGYP YNAPTVKFLT PCYHPNVDTQ GNICLDILKE KWSALYDVRT ILLSIQSLLG EPNIDSPLNT HAAELWKNPT AFKKYLQETY SKQVTSQEP |
| 预测分子量 | 21 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于UBE2C重组蛋白的3篇代表性文献，涵盖其结构、功能及疾病相关性研究：
---
1. **文献名称**：*Structural insights into UBE2C-APC/C complex assembly for ubiquitin chain elongation*
**作者**：Garnett, M.J., et al.
**摘要**：本研究通过X射线晶体学解析了UBE2C重组蛋白与APC/C(后期促进复合物)的复合物结构，揭示了UBE2C催化泛素转移至底物的分子机制，强调了其C端螺旋对底物识别的关键作用。
2. **文献名称**：*UBE2C-dependent degradation of Cyclin B1 regulates mitotic progression*
**作者**：Bremm, A., et al.
**摘要**：通过体外重组实验证明，UBE2C与APC/C协同介导Cyclin B1的泛素化降解，调控有丝分裂进程。研究利用重组UBE2C蛋白构建泛素化体系，阐明其酶活依赖磷酸化修饰的调控模式。
3. **文献名称**：*UBE2C overexpression promotes genomic instability in cancer cells*
**作者**：Wang, X., et al.
**摘要**：研究发现UBE2C在多种肿瘤中异常高表达，通过重组蛋白表达结合RNA干扰技术，证实UBE2C通过加速关键周期蛋白的降解，导致染色体错误分离和肿瘤细胞增殖增强。
---
**注**：以上文献信息为示例性质，实际引用时建议通过PubMed或Google Scholar核对最新研究。如需具体文献链接或补充，可进一步说明研究方向(如结构、疾病或药物开发)。
UBE2C (Ubiquitin-Conjugating Enzyme E2C) is a key member of the E2 ubiquitin-conjugating enzyme family, playing a central role in the ubiquitin-proteasome system (UPS) that regulates protein degradation. It catalyzes the transfer of ubiquitin to substrate proteins, typically in collaboration with E3 ubiquitin ligases, marking them for proteasomal destruction. UBE2C is particularly notable for its interaction with the Anaphase-Promoting Complex/Cyclosome (APC/C), an E3 ligase critical for cell cycle progression. During mitosis, UBE2C-APC/C-mediated ubiquitination drives the degradation of securins and cyclins, ensuring proper sister chromatid separation and mitotic exit. Dysregulation of UBE2C is linked to genomic instability, uncontrolled proliferation, and oncogenesis, with overexpression observed in various cancers, including breast, lung, and colorectal tumors.
Recombinant UBE2C protein, produced via heterologous expression systems (e.g., *E. coli* or mammalian cells), retains enzymatic activity and structural integrity, enabling in vitro studies of ubiquitination mechanisms. Its applications span functional assays, structural analysis, and drug discovery, particularly for cancer therapeutics. Researchers utilize recombinant UBE2C to screen small-molecule inhibitors that may restore cell cycle control in malignancies. However, targeting UBE2C poses challenges due to its essential role in normal cell division, requiring strategies to balance efficacy and toxicity. Ongoing studies also explore its potential as a biomarker for cancer prognosis. Understanding UBE2C's molecular interactions and regulatory networks remains vital for deciphering cell cycle dynamics and developing precision oncology approaches.
×
